News Roche’s autism drug granted FDA ‘breakthrough’ status A drug which could become the first ever treatment for Autism Spectrum Disorder has been granted Breakthrough Therapy Designation by the FDA.
News Gilead's twice-yearly HIV PrEP set for wider rollout The WHO has recommended Gilead's twice-yearly HIV PrEP drug lenacapavir, calling it 'transformational', but there are concerns about patient access.
Market Access The value of a partner, globally and locally A new podcast looks at recent trends related to drug approvals, as well as challenges and opportunities both small and large pharma companies face